Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q3 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7 million versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.